Drugs and the retina

Expert Opinion on Drug Safety

Volumn 3, Issue 3, 2004, Pages 249-259

  Constable, Simon ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse drug reaction (ADR); Hydroxychloroquine; Monitoring; Retinopathy; Vigatrin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CHLOROQUINE; CHLORPROMAZINE; CIDOFOVIR; DEFEROXAMINE; DIGOXIN; ETHAMBUTOL; FLUPHENAZINE; FOSCARNET; GANCICLOVIR; GENTAMICIN; HYDROXYCHLOROQUINE; MINOXIDIL; PHENOTHIAZINE; SILDENAFIL; TADALAFIL; TAMOXIFEN; THIORIDAZINE; TIAGABINE; TRIFLUOPERAZINE; VALGANCICLOVIR; VARDENAFIL; VIGABATRIN;

ANEMIA; ASTHENIA; BLOOD RETINA BARRIER; COLOR VISION DEFECT; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG MONITORING; DRUG SCREENING; EXTRAOCULAR MUSCLE; EYE PROTECTION; FANCONI RENOTUBULAR SYNDROME; FEVER; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPERTENSION; INFECTION; IRITIS; ISCHEMIC OPTIC NEUROPATHY; KIDNEY TUBULE DAMAGE; LIVER DYSFUNCTION; LIVER TOXICITY; METABOLIC ACIDOSIS; METABOLIC DISORDER; MUSCLE HYPOTONIA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUTROPENIA; OPTIC NERVE DISEASE; PAIN; PANCREATITIS; PHLEBITIS; PRESCRIPTION; PRURITUS; QT PROLONGATION; RETINA DEGENERATION; RETINITIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SKIN IRRITATION; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UVEITIS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

HUMANS; PHARMACEUTICAL PREPARATIONS; RETINA; RETINAL DISEASES;

EID: 2942695912     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.3.249     Document Type: Review

References (95)

1. SCHWARTZ SG, MIELER WF: Medications and retinal toxicity. Ophthalmol. Clin. North Am. (2002) 15(4):517-528.
2. FRAUNFELDER FW: Ocular adverse drug reactions. Expert Opin. Drug Saf. (2003) 2(4):411-420.
3. BOK D: The retinal pigment epithelium - a versatile partner in vision. J. Cell Sci. (1993) 17(Suppl.):189-195.
4. ZINN KM, MARMOR MF: The retinal pigment epithelium. Harvard University Press, Cambridge (1979).
5. LEBLANC B, JEZEQUEL S, DAVIES T, HANTON G, TARADACH C: Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul. Toxicol. Pharmacol. (1998) 28(2):124-132.
6. HARDING GF, SPENCER EL, WILD JM, CONWAY M, BOHN RL: Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology (2002) 58(8):1261-1265.
7. IANNETTI P, SPALICE A, PERLA FM, CONICELLA E, RAUCCI U, BIZZARRI B: Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics (2000) 106(4):838-842.
8. LAWDEN MC, EKE T, DEGG C, HARDING GF, WILD JM: Visual field defects associated with vigabatrin therapy. J. Neurol. Neurosurg. Psychiatry (1999) 67(6):716-722.
9. LUCHETTI A, AMADI A, GOBBI G: Visual field defects associated with vigabatrin monotherapy in children. J. Neurol. Neurosurg. Psychiatry (2000) 69(4):566.
10. MCDONAGH J, STEPHEN LJ, DOLAN FM et al.: Peripheral retinal dysfunction in patients taking vigabatrin. Neurology (2003) 61:1690-1694.
11. DANESHVAR H, RACETTE L, COUPLAND SG, KERTES PJ, GUBERMAN A, ZACKON D: Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Opthalmology (1999) 106(9):1792-1798.
12. EKE T, TALBOT JF, LAWDEN MC: Severe persistent visual field constriction associated with vigabatrin. Br. Med. J. (1997) 314:180-181.
13. WILSON EA, BRODIE MJ: Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. Br. Med. J. (1997) 14:1693.
14. WONG IC, MAWER GE, SANDER JW: Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose-dependent. Br. Med. J. (1997) 314:1693-1694.
15. BLACKWELL N, HAYLLAR J, KELLY G: Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. Br. Med. J. (1997) 314:1694.
16. HARDING GF: Severe persistent visual field constriction associated with vigabatrin. Br. Med. J. (1997) 314:1694.
17. SILLS GJ, BUTLER E, FORREST G, RATNARAJ N, PATSALOS PN, BRODIE MJ: Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia (2003) 44:886-892.
18. HARDUS P, VERDUIN WM, POSTMA G, STILMA JS, BERENDSCHOT TT, VAN VEELEN CW: Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br. J. Ophthalmol. (2000) 84:788-790.
19. JOHNSON MA, KRAUSS GL, MILLER NR, MEDURA M, PAUL SR: Visual function loss from vigabatrin: effect of stopping the drug. Neurology (2000) 55:40-45.
20. KÄLVIÄINEN R, NOUSIAINEN I: Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs (2001) 15:217-230.
21. MANUCHEHRI K, GOODMAN S, SIVITER L, NIGHTINGALE S: A controlled study of vigabatrin and visual abnormalities. Br. J. Ophthalmol. (2000) 84:499-505.
22. MALMGREN K, BEN-MENACHEM E, FRISEN L: Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia (2001) 42(5):609-615.
23. VIESTENZ A, VIESTENZ A, MARDIN CY: Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature. Ophthalmologe (2003) 100(5):402-405.
24. RUETHER K, PUNG T, KELLNER U, SCHMITZ B, HARTMANN C, SEELIGER M: Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch. Ophthalmol. (1998) 116(6):817-819.
25. MACKENZIE R, KLISTORNER A: Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin. Br. Med. J. (1998) 316:233.
26. WILSON E, BRODIE M: Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. Br. Med. J. (1997) 314:1693.
27. KRAUSS GL, JOHNSON MA, SHETH S, MILLER NR: A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J. Neurol. Neurosurg. Psychiatry (2003) 74(3):339-343.
28. COMMITTEE ON SAFETY OF MEDICINES/MEDICINES CONTROL AGENCY: Vigabatrin (Sabril): visual field defects. Curr. Probl. (1999) 25:13.
29. PAUL SR, KRAUSS GL, MILLER NR, MEDURA MT, MILLER TA, JOHNSON MA: Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia (2001) 42(4):525-530.
30. APPLETON RE: Guideline may help in prescribing vigabatrin. Br. Med. J. (1998) 317:1322.
31. HARDING GF: Severe persistent visual field constriction associated with vigabatrin. Br. Med. J. (1998) 316:232-233.
32. SPENCER EL, HARDING GF: Examining visual field defects in the paediatric population exposed to vigabatrin. Doc. Ophthalmol. (2003) 107(3):281-287.
33. ELMAN A, GULLBERG R, NILSSON E, RENDAHL I, WACHTMEISTER L: Chloroquine retinopathy in patients with rheumatoid arthritis. Scand. J. Rheumatol. (1976) 5:161-166.
34. MARKS JS, POWER BJ: Is chloroquine obsolete in treatment of rheumatic disease? Lancet (1979) 1:371-373.
35. MACKENZIE AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am. J. Med. (1983) 75(Suppl. 1A):40-45.
36. BRECKENRIDGE A: Risks and benefits of prophylactic antimalarial drugs. Br. Med. J. (1989) 299:1057-1058.
37. LANGE WR, FRANKENFIELD DL, MORIARTY-SHEEHAN M, CONTOREGGI CS, FRAME JD: No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am. J. Trop. Med. Hyg. (1994) 51:389-392.
38. SUNDELIN S, TERMAN A: Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS (2002) 110(6):481-489.
39. SHROYER N, LEWIS R, LUPSKI JR: Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am. J. Ophthalmol. (2001) 131(6):761-766.
40. PENROSE PJ, TZEKOV RT, SUTTER EE et al.: Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina (2003) 23(4):503-512.
41. BERNSTEIN HN: Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am. J. Med. (1983) 75 (Suppl. 1A): 25-34.
42. OGAWA S, KURUMATANI N, SHIBAIKE N, YAMAZOE S: Progression of retinopathy long after cessation of chloroquine therapy. Lancet (1979) 1:1408.
43. EASTERBROOK M: Ocular effects and safety of antimalarial agents. Am. J. Med. (1988) 85(Suppl. 4A):23-29.
44. EHRENFELD M, NESHER R, MERIN S: Delayed-onset chloroquine retinopathy. Br. J. Ophthalmol. (1986) 70:281-283.
45. PERCIVAL S, MEANCOCK I: Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis. Br. Med. J. (1968) 3:579-584.
46. JONES SK: Ocular toxicity and hydroxychloroquine: guidelines for screening. Br. J. Dermatol. (1999) 140(1):3-7.
47. ROYAL COLLEGE OF OPHTHALMOLOGISTS: Chloroquine, hydroxychloroquine and the eye. London: College of Ophthalmologists (1993).
48. AMERICAN COLLEGE OF RHEUMATOLOGY: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. (1996) 39:723-731.
49. SAMANTA A, GOH L, BAWENDI A: Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Rheumatology (Oxford) (2004) 43:346-348.
50. BERNATSKY S, PINEAU C, JOSEPH L, CLARKE A: Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort. J. Rheumatol. (2003) 30(8):1756-1760.
51. SHIPLEY M, SILMAN A: Sbould patients on hydroxychloroquine have their eyes examined regularly? Br. J. Rheumatol. (1997) 36(5):514-515.
52. MORSMAN CD, LIVESEY SJ, RICHARDS IM, JESSOP JD, MILLS PV: Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye (1990) 4(Pt 4):572-576.
53. INOVE F: Adverse reactions of antipsychotic drugs. Drug Intell. Clin. Pharm. (1979) 13:198-208.
54. OSHIKA T: Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf. (1995) 12(4):256-263.
55. CAMERON MF: Skin and eye changes associated with chlorpromazine therapy. Med. J. Aust. (1966) 1:478-480.
56. REBOTON J, WEEKLEY RD, BYLENGA ND et al.: Pigmentary retinopathy and iridocycloplegia in psychiatric patients. J. Neuropsychiatry (1962) 3:311-316.
57. WEEKLEY RD, POTTS AM, REBOLON J, MAY RH: Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch. Ophthalmol. (1960) 61:95-106.
58. SCOTT AW: Retinal pigmentation in patients receiving thioridazine. Arch. Ophthalmol. (1963) 70:775-778.
59. SPITERI MA, JAMES DG: Adverse ocular reactions to drugs. Postgrad. Med. J. (1983) 59:343-349.
60. CROMBIE AL: Drugs causing eye problems. Prescr. J. (1981) 21:222-227.
61. FORNARO P, CALABRIA G, CORALLO G, PICOTTI GB: Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc. Ophthalmol. (2002) 105(1):41-49.
62. MARMOR MF: Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J. Ophthalmol. (1990) 74:739-742.
63. POWER WJ, TRAVERS SP, MOONEY DJ: Welding arc maculopathy and fluphenazine. Br. J. Ophthalmol. (1991) 75:433-435.
64. FINK HA, MACDONALD R, RUTKS IR, NELSON BD, WILT TJ: Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch. Intern. Med. (2002) 162:1349-1361.
65. VOBIG MA, KLOTZ T, STAAK M, BARTZ-SCHMIDT KU, ENGELMANN U, WALTER P: Retinal side-effects of sildenafil. Lancet (1999) 353:375.
66. MARMOR MF: Sildenafil (Viagra) and ophthalmology. Arch. Ophthalmol. (1999) 117:518-519.
67. CUNNINGHAM AV, SMITH KH: Anterior ischemic optic neuropathy associated with viagra. J. Neuroophthalmol. (2001) 21(1):22-25.
68. MARMOR MF, KESSLER R: Sildenafil (Viagra) and ophthalmology. Surv. Ophthalmol. (1999) 44(2):153-162.
69. CAMPOCHIARO PA, LIM JI: Aminoglycoside toxicity in the treatment of endophthalmitis. The Aminoglycoside Toxicity Study Group. Arch. Ophthalmol. (1994) 112:48-53.
70. JACKSON TL, WILLIAMSON TH: Amikacin retinal toxicity. Br. J. Ophthalmol. (1999) 83(10):1199-1200.
71. PORTER JB, HUEHNS ER: The toxic effects of desferrioxamine. Baillieres Clin. Haematol. (1989) 2(2):459-474.
72. WELEBER RG, SHULTS WT: Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch. Ophthalmol. (1981) 99(9):1568-1572.
73. YEN MY, WANG AG, CHIANG SC, LIU JH: Ethambutol retinal toxicity: an electrophysiologic study J. Formos. Med. Assoc. (2000) 99(8):630-634.
74. GOMBOS GM: Bilateral optic neuritis following minoxidil administration. Ann. Ophthalmol. (1983) 15:259-261.
75. LAZZARONI F, SCOROLLI L, PIZZOLEO CF et al.: Tamoxifen retinopathy: does it really exist? Graefes Arch. Clin. Exp. Ophthalmol. (1998) 236(9):669-673.
76. JACOBSON MA: Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. (1997) 337:105-114.
77. DHILLON B: The management of cytomegalovirus retinitis in AIDS. Br. J. Ophthalmol. (1994) 78:66-69.
78. WHITCUP SM: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA (2000) 283:653-657.
79. JOUAN M, SAVES M, TUBIANA R et al.: Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy AIDS (2001) 15:23-31.
80. CURI AL, MURALHA A, MURALHA L, PAVESIO C: Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy. Br. J. Ophthalmol. (2001) 85:471-473.
81. PLOSKER GL, NOBLE S: Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs (1999) 58:325-345.
82. MCGAVIN JK, GOA KL: Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs (2001) 61(8):1153-1183.
83. CURRAN M, NOBLE S: Valganciclovir. AIDS new drug profile. Drugs (2001) 61(8):1145-1150.
84. JACOBSON MA, CAUSEY D, POLSKY B et al.: A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J. Infect. Dis. (1993) 168:444-448.
85. GAUB J, PEDERSEN P, POULSEN AG et al.: The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS (1987) 1:27-33.
86. BEAUFILS H, DERAY G, KATLAMA C et al.: Foscarnet and crystals in glomerular capillary lumens. Lancet (1990) 336:755.
87. DERAY G, KATLAMA C, DOHIN E: Prevention of foscarnet nephrotoxicity. Ann. Intern. Med. (1990) 113:332.
88. FARESE RV Jr, SCHAMBELAN M, HOLLANDER H, STRINGARI S, JACOBSON MA: Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann. Intern. Med. (1990) 112:955-956.
89. CONN J, COLMAN P, BROWN G, STREET A, BATE K: Nephrogenic diabetes insipidus associated with foscarnet - a case report. J. Antimicrob. Chemother. (1996) 37:1179-1181.
90. CIHLAR T, HO ES, LIN DC, MULATO AS: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):641-648.
91. VITTECOQ D, DUMITRESCU L, BEAUFILS H, DERAY G: Fanconi syndrome associated with cidofovir therapy. Antimicrob. Agents Chemother. (1997) 41:1846.
92. SCHLIEFER K, ROCKSTROH JK, SPENGLER U, SAUERBRUCH T: Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet (1997) 350:413-414.
93. TSENG AL, MORTIMER CB, SALIT IE: Iritis associated with intravenous cidofovir. Ann. Pharmacother. (1999) 33:167-171.
94. AMBATI J, WYNNE KB, ANGERAME MC, ROBINSON MR: Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br. J. Ophthalmol. (1999) 83:1153-1158.
95. SONG MK, AZEN SP, BULEY A et al.: Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am. J. Ophthalmol. (2003) 136(4):696-702.